The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

被引：0
|
作者：
Ashok Jha
Alex Upton
William C. N. Dunlop
Ron Akehurst
机构：
[1] Mundipharma International Ltd.,School of Health and Related Research (ScHARR)
[2] Abacus International,undefined
[3] University of Sheffield,undefined
[4] BresMed Health Solutions Limited,undefined
[5] Northchurch Business Centre,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
Ankylosing spondylitis; Biosimilar; Crohn’s disease; Infliximab; Psoriasis; Psoriatic arthritis; Remicade; Remsima; Rheumatoid arthritis; Ulcerative colitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：742 / 756
页数：14
相关论文
共 50 条
  • [31] Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases
    Braun, Juergen
    Kudrin, Alex
    IMMUNOTHERAPY, 2015, 7 (02) : 73 - 87
  • [32] Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia
    August Cesarec
    Robert Likić
    Applied Health Economics and Health Policy, 2017, 15 : 277 - 286
  • [33] BUDGET IMPACT ANALYSIS OF AN ETANERCEPT BIOSIMILAR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN EUROPE
    Ruff, L.
    Rezk, M. F.
    Uhlig, T.
    Gommers, J. W.
    VALUE IN HEALTH, 2015, 18 (07) : A639 - A639
  • [34] Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia
    Cesarec, August
    Likic, Robert
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (02) : 277 - 286
  • [35] BUDGET IMPACT OF SUBSTITUTING BIOSIMILAR TRASTUZUMAB (CT-P6) IN TREATING GASTRIC CANCER AND BREAST CANCER IN 28 EUROPEAN COUNTRIES
    Suh, D.
    Lee, S.
    Suh, D.
    VALUE IN HEALTH, 2018, 21 : S25 - S25
  • [36] Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
    Kanters, Tim A.
    Stevanovic, Jelena
    Huys, Isabelle
    Vulto, Arnold G.
    Simoens, Steven
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [37] Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from a Central European nationwide cohort
    Balint, A.
    Farkas, K.
    Rutka, M.
    Vegh, Z.
    Kurti, Z.
    Banai, J.
    Bene, L.
    Gasztonyi, B.
    Kristof, T.
    Lakatos, L.
    Miheller, P.
    Palatka, K.
    Patai, A.
    Salamon, A.
    Szamosi, T.
    Szepes, Z.
    Toth, G. T.
    Vincze, A.
    Bor, R.
    Milassin, A.
    Nagy, F.
    Kolar, M.
    Bortlik, M.
    Duricova, D.
    Hruba, V.
    Lukas, M.
    Mitrova, K.
    Malickova, K.
    Lukas, M.
    Lakatos, P. L.
    Molnar, T.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S31 - S31
  • [38] Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort
    Balint, Anita
    Rutka, Mariann
    Vegh, Zsuzsanna
    Kurti, Zsuzsanna
    Gecse, Krisztina B.
    Banai, Janos
    Bene, Laszlo
    Gasztonyi, Beata
    Kristof, Tunde
    Lakatos, Laszlo
    Miheller, Pal
    Palatka, Karoly
    Patai, Arpad
    Salamon, Agnes
    Szamosi, Tamas
    Szepes, Zoltan
    Toth, Gabor Tamas
    Vincze, Aron
    Bor, Renata
    Milassin, Agnes
    Fabian, Anna
    Nagy, Ferenc
    Kolar, Martin
    Bortlik, Martin
    Duricova, Dana
    Hruba, Veronika
    Lukas, Martin
    Mitrova, Katarina
    Malickova, Karin
    Lukas, Milan
    Lakatos, Peter L.
    Molnar, Tamas
    Farkas, Klaudia
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (08) : 885 - 890
  • [39] TREATMENT PATTERNS OF METASTATIC MELANOMA IN FIVE EUROPEAN COUNTRIES
    Burudpakdee, C.
    Zhao, Z.
    Seetasith, A.
    Ma, Q.
    Campos Tapias, I
    Barber, B. L.
    VALUE IN HEALTH, 2016, 19 (03) : A172 - A172
  • [40] Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice
    Tweehuysen, L.
    van den Bemt, B. J. F.
    van Ingen, I. L.
    de Jong, A. J. L.
    van der Laan, W. H.
    van den Hoogen, F. H. J.
    den Broeder, A. A.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345